On Wednesday, Travere Therapeutics hit an important technical milestone, with its Relative Strength (RS) Rating moving into the 80-plus percentile with an improvement to 83, up from 80 the day before.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.
While Travere Therapeutics is not near a proper entry right now, see if it goes on to form and break out from a proper chart pattern.
Travere Therapeutics reported 0% earnings growth in its most recent report. Revenue increased 98%.
The company earns the No. 124 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
